C12N 2710/16234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16234 (Use of virus or viral component as vaccine) appears on 99 US grants and 203 published applications in this corpus.
Search patents in C12N- Granted patents
- 99
- Published applications
- 203
- Assignees
- 133
- Inventors
- 407
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 3 | 3 |
| 2003 | 2 | 2 |
| 2004 | 1 | 6 |
| 2005 | 0 | 3 |
| 2006 | 2 | 3 |
| 2007 | 2 | 3 |
| 2008 | 1 | 2 |
| 2009 | 1 | 5 |
| 2010 | 1 | 0 |
| 2011 | 0 | 7 |
| 2012 | 2 | 4 |
| 2013 | 1 | 1 |
| 2014 | 1 | 4 |
| 2015 | 2 | 8 |
| 2016 | 2 | 6 |
| 2017 | 2 | 11 |
| 2018 | 7 | 9 |
| 2019 | 9 | 17 |
| 2020 | 6 | 8 |
| 2021 | 9 | 18 |
| 2022 | 3 | 14 |
| 2023 | 8 | 21 |
| 2024 | 15 | 19 |
| 2025 | 6 | 21 |
| 2026 | 6 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Compositions, devices and methods for inducing immune responses to infectious agents16 Jun 2026US 12,653,888 B2Sigilon Therapeutics, Inc.
- TCR constructs specific for EBV-derived antigens16 Jun 2026US 12,655,191 B2Max-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft
- Fusion antibody for presenting antigen-derived T cell antigen epitope or peptide containing same on cell surface, and composition comprising same31 Mar 2026US 12,590,156 B2Ajou University Industry-Academic Cooperation Foundation
- T cell antigen receptor, multimeric complex thereof, and preparation method therefor and use thereof24 Mar 2026US 12,583,910 B2Bristar Immunotech Limited
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Epstein-barr virus mrna vaccines6 Aug 2026US 2026/0224691 A1ModernaTX, Inc.
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Compositions comprising polyinosinic-polycytidylic acid, epstein-barr (ebv) virus-like particles and ebv-specific car-t cells for improving immune cell therapy18 Jun 2026US 2026/0166117 A1Zeno Therapeutics Pte. Ltd.
- Immunogenic compositions for epstein-barr virus proteins30 Apr 2026US 2026/0115277 A1Merck Sharp & Dohme Corp.
Most cited
By later US patents
- Varicella-zoster virus as a live recombinant vaccine69US 5,310,668 AMerck & Co., Inc. · 1994
- Human immunodeficiency virus decoy33US 5,334,394 AThe Regents of the University of California · 1994
- Therapeutic calcium phosphate particles and methods of manufacture and use32US 6,355,271 B1BioSante Pharmaceuticals, Inc. · 2002
- Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/22024US 6,432,679 B1The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. · 2002
- Viral decoy vaccine23US 5,178,882 AThe Regents of the University of California · 1993